Juva Life Advances JUVA-019 into Preclinical Development for Inflammatory Disease
Juva Life Inc. announced the advancement of JUVA-019 into pre-clinical development, a non-cannabinoid molecule showing strong anti-inflammatory properties. Verified studies affirm that JUVA-019 operates effectively without cannabinoids. The next phase involves exploring structure-activity relationships and pharmacokinetics in various disease models, initially targeting analgesia. The global anti-inflammatory therapeutics market is projected to reach USD $191.4 billion by 2027, highlighting the commercial potential of JUVA-019.
- Advancement of JUVA-019 into pre-clinical development.
- Demonstrated potent anti-inflammatory properties.
- JUVA-019 effective without dependence on cannabinoids.
- Potential to capture market share in an expanding anti-inflammatory therapeutics market projected at USD $191.4 billion by 2027.
- None.
JUVA-019 Observed Potency Leads to Advancement Along Drug Development Pathway
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, announced today the advancement of JUVA-019 from discovery into pre-clinical development.
JUVA-019 is a small, non-cannabinoid molecule which has previously demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation. Additional laboratory studies have now been completed verifying these initial findings, and furthermore suggest that JUVA-019 is a potent stand-alone compound, whose anti-inflammatory activity is not dependent on synergism with known cannabinoids.
“We are excited about the nomination of JUVA-019 to formal development in which we will conduct detailed structure activity relationships on the JUVA-019 chemical motif to optimize its anti-inflammatory and drug-like properties,” stated Doug Chloupek, Juva Founder & CEO. “This is an important advancement in the validation of our platform, in that it suggests that there are unappreciated non-cannabinoid molecules in cannabis that may be both clinically and commercially valuable.”
Leading up to this advancement, researchers at Juva conducted multiple studies, including a previously announced comparative study which explored multiple modes of action for JUVA-019. The goal of the study was to evaluate inhibition of IL1-beta and IFNg biomarkers, among others when introduced to JUVA-019 as a stand-alone molecule, which created a baseline. Additional studies now confirm that JUVA-019 does not require cannabinoids to elicit the observed anti-inflammatory effects.
“Our next steps will follow the prescriptive advancement of JUVA-019 through the gold standard pre-clinical and non-clinical drug development process, initially focusing on exploring the structural requirements for activity,” stated Sanjeev Gangwar, Ph.D., Vice President of Chemistry at Juva. “In parallel we will explore PD/PK relationships in a battery of in vivo models of human disease, with an initial focus on analgesia.”
The Company’s business focus is the development of safe and effective treatments targeting the global anti-inflammatory therapeutics market is estimated to reach USD
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
FAQ
What is the significance of JUVA-019's advancement in Juva Life's pipeline?
How does JUVA-019 work as an anti-inflammatory treatment?
What are the next steps for JUVA-019's development?
What market opportunity does JUVA-019 target?
What was confirmed by recent studies on JUVA-019?
